NCT01090973终止2 期
Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Participants With Desired Response
研究概览
简要总结
The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
详细描述
Response Assessment for Mantle Cell Lymphoma
Based on the International Workshop to Standardize Response Criteria to non-hodgkin's lymphoma (NHL) (Cheson, JCO 1999) a complete hematologic remission will be defined as the following:
- Disappearance of all evidence of disease.
- Any positron emission tomography (PET)+ mass prior to therapy must be PET negative after treatment.
- No palpable spleen or liver
- If bone marrow involvement prior to therapy, must document clear bone marrow.
Partial response will be defined as:
- No new areas of disease on clinical exam and regression of previous areas of disease
- Greater than or equal to 50% decrease in the size of prior disease areas per measurement on computed tomography (CT) scan
- No new PET+ areas on PET scan
- No increase in size of liver or spleen
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- •Patients must meet the following laboratory criteria (unless dysfunction is due to organ infiltration by lymphoma):
- •ANC ≥ 1.5 x 10^9/L
- •Hemoglobin ≥ 9 g/dl
- •Platelets ≥ 75 x 10^9/L
- •Calculated CrCl ≥50 mL/min (MDRD Formula)
- •Total serum calcium ≥ LLN
- •Total serum magnesium ≥ LLN
- •Aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
- •Serum bilirubin ≤1.5 x ULN
- •Serum potassium ≥ LLN
- •Thyroid stimulating hormone (TSH) ≥ lower limit of normal (LLN) and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.
- •Baseline multiple uptake gate acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
- •Documented MCL by biopsy or CLL by biopsy or flow cytometry.
- •Relapsed or refractory disease despite 1 or more lines of therapy.
排除标准
- •Prior histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
- •Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
- •Peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 3
- •Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- •Patients with congenital long QT syndrome
- •History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment)
- •History of ventricular fibrillation or torsade de pointes
- •Bradycardia defined as HR< 50 bpm. Patients with pacemakers are eligible if HR ≥ 50 bpm.
- •Screening 12 lead electrocardiogram (ECG) with a QTc > 450 msec
- •Right bundle branch block + left anterior hemiblock (bifascicular block)
- •Myocardial infarction or unstable angina ≤ 6 months prior to starting study drug
- •Other clinically significant heart disease (e.g., congestive heart failure (CHF) New York Heart Association (NYHA) class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH589
- •Patients with diarrhea > CTCAE grade 1
- •Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
- •Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
- •Have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (which ever is longer) and who have not recovered from side effects of those therapies.
- •Have received either immunotherapy within < 8 weeks; chemotherapy within < 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within < 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies.
- •Have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- •Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). WOCBP must have a negative serum pregnancy test within 24 hours of receiving the first dose of study medication.
- •Male patients whose sexual partners are WOCBP not using effective birth control
- •Prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
- •Known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- •Significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff.
- •Have not received prior therapy for aggressive MCL or CLL.
- •No documentation of disease refractoriness (i.e. progression of disease despite current therapy or recurrence within 3 months of last treatment) or relapse despite prior therapy.
研究组 & 干预措施
Oral drug treatment
Experimental
LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
干预措施: LBH589 (Drug)
结局指标
主要结局
Number of Participants With Desired Response
时间窗: 8 weeks (2 cycles) unless treatment continues due to partial or complete response
Investigators intended to assess the rate of overall and complete response by World Health Organization (WHO) classification in patients with relapsed or refractory aggressive mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). WHO Performance Scale Measures levels of patient capability: 0 Normal activity; 1 Symptoms, but nearly fully ambulatory; 2 Some bed time, but needs to be in bed \<50% of normal daytime; 3 Needs to be in bed \>50% of normal daytime; 4 Unable to get out of bed.
次要结局
- Number of Participants With Complete Response (CR) and Partial Response (PR)(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
- Response Duration(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
- Progression Free Survival (PFS) Estimate(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
- Number of Participants With Prolonged Corrected QT (QTc) Interval(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
- Number of Participants With Improved Blood and Lymphatic Evaluation Results(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
- Number of Participants With Adverse Events (AEs)(8 weeks (2 cycles) unless treatment continues due to partial or complete response)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer PatientsProstate CancerNCT00895466Pepscan Therapeutics12
终止
1 期
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)Acute GvHDNCT01530256CSL Behring3
Unknown
1 期
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaHepatocellular CarcinomaNCT04233840National Taiwan University Hospital72
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
已完成
2 期
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)NCT01842646H. Lee Moffitt Cancer Center and Research Institute35